Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the best high short interest stocks with biggest upside potential.
Mineralys Therapeutics Inc. (MLYS)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 7,323,750 | $265,778,888 | 2.72% | |
| 2. | Samsara BioCapital Srini Akkaraju And Michael Dybbs | 5,871,018 | $213,059,243 | -7% | 21.98% |
| 3. | Caligan Partners David Johnson | 2,772,654 | $100,619,614 | 8.28% | |
| 4. | 2,298,400 | $83,408,936 | 6.87% | ||
| 5. | Laurion Capital Management Benjamin A. Smith | 1,713,485 | $62,182,371 | -1% | 2.32% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.50 | 588,235 | $14,999,992.50 | 588,235 | 2025-09-04 | Filing | |
| $25.50 | 1,176,470 | $29,999,985.00 | 5,456,521 | 2025-09-04 | Filing | |
| $13.50 | 259,259 | $3,499,996.50 | 8,903,838 | 2025-03-13 | Filing | |
| $13.50 | 600,000 | $8,100,000.00 | 5,674,916 | 2025-03-13 | Filing | |
| $13.50 | 600,000 | $8,100,000.00 | 5,674,916 | 2025-03-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.59 | 417 | $11,505.03 | 44,089 | 2026-02-17 | Filing | |
| $27.58 | 6,348 | $175,100.06 | 44,089 | 2026-02-13 | Filing | |
| $27.33 | 4,166 | $113,856.78 | 50,437 | 2026-02-13 | Filing | |
| $27.33 | 3,541 | $96,775.53 | 50,437 | 2026-02-13 | Filing | |
| $29.64 | 521 | $15,441.76 | 50,437 | 2026-02-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,903,838 | $286,830,281 | 92.37% | |
| 2. | 5,057,509 | $183,537,002 | 0.01% | |
| 3. | 4,327,678 | $157,051,434 | 0% | |
| 4. | 3,352,880 | $121,676,015 | 0% | |
| 5. | 3,184,999 | $115,583,614 | 0% |
News See All
11 Best High Short Interest Stocks With Biggest Upside Potential
On January 27, Sherry Paul, a senior portfolio manager at Morgan Stanley, appeared on CNBC's 'Closing Bell' to discuss whether more volatility is ahead, following a volatile week in the market.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2025 Earnings Call Transcript
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2025 Earnings Call Transcript November 10, 2025Mineralys Therapeutics, Inc. beats earnings expectations.
12 Best Performing Healthcare Stocks to Buy Right Now
Spending on healthcare in the US is predicted to hit $5.3 trillion this year, making it one of the largest in the world.
Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak
Mineralys surged to a new all-time high on Tuesday, as investors gobbled up shares after one of its counterparts posted positive trial results for its aldosterone synthase inhibitor (ASI), with optimism...
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q2 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the Mineralys Second Quarter 2025 Earnings Call. [Operator Instructions] It is now my pleasure to introduce your host, Dan Ferry of LifeSci Advisors. Thank you.
12 Small Cap Stocks with High Upside Potential
The trade war saga between the U.S. and China appears to be nearing a conclusion, as China’s Ministry of Commerce shared details on the trade deal on June 27.
Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is one of the 12 Small Cap Stocks with High Upside Potential. On June 17, Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Mineralys First Quarter 2025 Earnings Conference Call. At this time, all lines are in listen-only mode.
Hedge Fund Resource Center